Hall Capital Management Co. Inc. decreased its holdings in Abbott Laboratories (NYSE:ABT) by 2.4% in the second quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 28,864 shares of the healthcare product maker’s stock after selling 695 shares during the period. Hall Capital Management Co. Inc.’s holdings in Abbott Laboratories were worth $1,403,000 as of its most recent SEC filing.

Other institutional investors have also made changes to their positions in the company. Heritage Trust Co raised its holdings in Abbott Laboratories by 10.1% during the 2nd quarter. Heritage Trust Co now owns 2,175 shares of the healthcare product maker’s stock valued at $106,000 after buying an additional 200 shares during the last quarter. Winfield Associates Inc. raised its holdings in Abbott Laboratories by 3.9% during the 2nd quarter. Winfield Associates Inc. now owns 2,382 shares of the healthcare product maker’s stock valued at $116,000 after buying an additional 89 shares during the last quarter. Thompson Davis & CO. Inc. raised its holdings in Abbott Laboratories by 17.7% during the 2nd quarter. Thompson Davis & CO. Inc. now owns 2,463 shares of the healthcare product maker’s stock valued at $120,000 after buying an additional 370 shares during the last quarter. JFS Wealth Advisors LLC raised its holdings in Abbott Laboratories by 349.0% during the 2nd quarter. JFS Wealth Advisors LLC now owns 2,694 shares of the healthcare product maker’s stock valued at $131,000 after buying an additional 2,094 shares during the last quarter. Finally, Motco raised its holdings in Abbott Laboratories by 213.7% during the 2nd quarter. Motco now owns 2,880 shares of the healthcare product maker’s stock valued at $140,000 after buying an additional 1,962 shares during the last quarter. 71.01% of the stock is owned by institutional investors.

Abbott Laboratories (NYSE ABT) opened at $54.64 on Friday. The company has a debt-to-equity ratio of 0.72, a current ratio of 2.69 and a quick ratio of 2.26. Abbott Laboratories has a 1-year low of $37.90 and a 1-year high of $56.69. The company has a market cap of $95,106.44, a price-to-earnings ratio of 22.67, a price-to-earnings-growth ratio of 2.05 and a beta of 1.06.

Abbott Laboratories (NYSE:ABT) last issued its quarterly earnings data on Wednesday, October 18th. The healthcare product maker reported $0.66 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.65 by $0.01. Abbott Laboratories had a net margin of 8.37% and a return on equity of 13.98%. The business had revenue of $6.83 billion during the quarter, compared to analyst estimates of $6.72 billion. During the same period in the prior year, the business earned $0.59 EPS. The company’s revenue for the quarter was up 28.8% on a year-over-year basis. sell-side analysts predict that Abbott Laboratories will post 2.49 earnings per share for the current fiscal year.

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, November 15th. Shareholders of record on Friday, October 13th were issued a $0.265 dividend. The ex-dividend date was Thursday, October 12th. This represents a $1.06 annualized dividend and a yield of 1.94%. Abbott Laboratories’s dividend payout ratio (DPR) is presently 83.47%.

A number of equities research analysts recently commented on ABT shares. Cowen reiterated a “buy” rating and set a $55.00 price target on shares of Abbott Laboratories in a report on Thursday, August 17th. Citigroup started coverage on shares of Abbott Laboratories in a report on Thursday, August 17th. They set a “neutral” rating and a $53.00 price target for the company. BMO Capital Markets reiterated a “hold” rating and set a $53.00 price target on shares of Abbott Laboratories in a report on Friday, September 1st. Zacks Investment Research upgraded shares of Abbott Laboratories from a “hold” rating to a “buy” rating and set a $58.00 price target for the company in a report on Friday, September 22nd. Finally, Wells Fargo & Company upped their price target on shares of Abbott Laboratories from $57.00 to $64.00 and gave the company an “outperform” rating in a report on Thursday, September 28th. Eight analysts have rated the stock with a hold rating and ten have given a buy rating to the company. Abbott Laboratories presently has a consensus rating of “Buy” and an average price target of $56.81.

In related news, Chairman Miles D. White sold 276,886 shares of the stock in a transaction dated Wednesday, December 6th. The shares were sold at an average price of $54.41, for a total value of $15,065,367.26. Following the completion of the transaction, the chairman now directly owns 3,677,913 shares in the company, valued at approximately $200,115,246.33. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Jaime Contreras sold 52,700 shares of the stock in a transaction dated Friday, September 22nd. The stock was sold at an average price of $51.97, for a total transaction of $2,738,819.00. Following the completion of the transaction, the insider now owns 58,739 shares of the company’s stock, valued at $3,052,665.83. The disclosure for this sale can be found here. Insiders sold a total of 588,013 shares of company stock valued at $32,023,946 over the last 90 days. Company insiders own 0.76% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This report was first reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this report on another website, it was illegally copied and reposted in violation of US & international trademark and copyright laws. The original version of this report can be accessed at https://www.thecerbatgem.com/2017/12/10/hall-capital-management-co-inc-cuts-stake-in-abbott-laboratories-abt.html.

About Abbott Laboratories

Abbott Laboratories is engaged in the discovery, development, manufacture and sale of a range of healthcare products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products. Its Established Pharmaceutical Products include a range of branded generic pharmaceuticals manufactured around the world and marketed and sold outside the United States.

Institutional Ownership by Quarter for Abbott Laboratories (NYSE:ABT)

Receive News & Stock Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related stocks with our FREE daily email newsletter.